Cellectar Biosciences Inc (STU:NV4)
€ 0.234 -0.58 (-49.15%) Market Cap: 11.96 Mil Enterprise Value: -7.16 Mil PE Ratio: 0 PB Ratio: 8.03 GF Score: 38/100

Cellectar Biosciences Inc at EBD Group Biotech Showcase Transcript

Jan 09, 2024 / 10:00PM GMT
Release Date Price: €3.02 (-1.31%)
Erik Clausen CG Life;Moderator

Hello, everybody, and welcome. I'm Erik Clausen with CG Life. I'll be announcing the company presentations today.

We're really thrilled. Our first and next presenting company is Cellectar Biosciences, hailing from Florham Park, New Jersey. Cellectar Biosciences is focused on hematology, oncology, orphan and rare disease. Presenting for Cellectar Biosciences is their President and CEO, James Caruso.

And please stick around afterwards. A breakout will follow on public breakout room two. Thank you.

James Caruso Cellectar Biosciences
Inc. - President & CEO

Thank you, Erik. It's a pleasure to be here and presenting at Biotech Showcase 2024. Certainly appreciative of your participation in the presentation as well.

As you may or may not know, Cellectar Biosciences is traded on the Nasdaq Exchange under CLRB ticker symbol. Here's our obligatory Safe Harbor statement. I would always, of course, direct your attention to our public filings with the SEC.

As many of you know, Cellectar

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot